Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys 1,500 Shares of Stock

by · The Markets Daily

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) CEO Snehal Patel bought 1,500 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was purchased at an average price of $14.63 per share, with a total value of $21,945.00. Following the transaction, the chief executive officer now owns 5,536,102 shares in the company, valued at approximately $80,993,172.26. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

  • On Monday, August 5th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $13.18 per share, with a total value of $72,490.00.
  • On Tuesday, July 23rd, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $15.89 per share, with a total value of $23,835.00.

Greenwich LifeSciences Price Performance

NASDAQ:GLSI opened at $13.86 on Wednesday. Greenwich LifeSciences, Inc. has a 12-month low of $7.58 and a 12-month high of $21.44. The firm has a market capitalization of $178.52 million, a P/E ratio of -19.25 and a beta of 1.61. The business has a 50 day simple moving average of $14.39 and a 200 day simple moving average of $15.02.

Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). Research analysts anticipate that Greenwich LifeSciences, Inc. will post -0.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their price objective on Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, August 23rd.

Get Our Latest Research Report on Greenwich LifeSciences

Institutional Trading of Greenwich LifeSciences

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers bought a new stake in Greenwich LifeSciences during the 2nd quarter valued at $117,000. Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences during the 2nd quarter valued at $264,000. Finally, Vanguard Group Inc. raised its stake in Greenwich LifeSciences by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after acquiring an additional 1,420 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Read More